Research programme: efomycines - Bayer
Alternative Names: Efomycines research programme - BayerLatest Information Update: 20 Aug 2001
At a glance
- Originator Bayer
- Class
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 20 Aug 2001 No-Development-Reported for Psoriasis in Germany (Unknown route)
- 08 Jan 1999 New profile
- 08 Jan 1999 Preclinical development for Psoriasis in Germany (Unknown route)